Cas:53595-99-6 2-chloro-N-(4-methoxyphenyl)aniline manufacturer & supplier

Chemical Name:2-chloro-N-(4-methoxyphenyl)aniline

CAS.NO:53595-99-6

Synonyms:N-(4-methoxyphenyl)-2-chloroaniline;N-(2-chlorophenyl)-4-methoxyaniline;T0400-1807;HMS1410F11;4-methoxy-2′-chlorodiphenylamine;4-(2′-chlorophenylamino)-1-methoxybenzene;2′-chloro-4-methoxydiphenylamine;(2-chlorophenyl)(4-methoxyphenyl)amine

Molecular Formula:C₁₃H₁₂ClNO

Molecular Weight:233.69300

HS Code:2922199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:21.26000

Exact Mass:233.06100

LogP:4.16520

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(4-methoxyphenyl)-2-chloroaniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2-chlorophenyl)(4-methoxyphenyl)amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2′-chloro-4-methoxydiphenylamine Use and application,2′-chloro-4-methoxydiphenylamine technical grade,usp/ep/jp grade.

Related News: Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API. 2-chloro-N-(4-methoxyphenyl)aniline manufacturer The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 2-chloro-N-(4-methoxyphenyl)aniline supplier The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 2-chloro-N-(4-methoxyphenyl)aniline vendor The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. 2-chloro-N-(4-methoxyphenyl)aniline factory Among the APIs we produce, there is an API which passes through over ten kinds of intermediates in a process when it changes from being a raw material into an API.